ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
ALX ONCOLOGY HOLDINGS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.14+0.08 (+7.55%)
Close on Oct 19, 2026
- Market cap
- $154.63M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -25.5% | -145.7% | |
| Return on assets | – | -20.5% | -98.3% | |
| Current ratio | – | 70.28 | 2.07 | |
| Debt to equity | – | – | 0.38 | |
| Net debt to EBITDA | – | – | 0.06× | |
| Interest coverage | – | – | -64.9× | |
| Capex to revenue | – | 2.6% | – | |
| Diluted shares | – | 18M | 54M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Alx Oncology generated $493.74M from operations and spent $4.03M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$493.74M
Used
$4.03M
Capital expenditure$4.03M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3869.7%
×Asset turnover0.01×
×Equity multiplier1.24×
=Return on equity, FY2020-25.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2020 | -3869.7% | 0.01× | 1.24× | -25.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$101.70M
- Cash generatingOperating cash flow above zero-$84.14M
- Return on assets improvedROA up on the prior year-55.6% → -68.8%
- Earnings backed by cashOperating cash flow above net income-$84.14M vs -$101.70M
- Less leverageLong-term debt to assets fell6.4% → 7.7%
- Better liquidityCurrent ratio rose7.26 → 2.07
- No dilutionShare count did not rise52M → 54M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –